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Background/aim: Impaired lymphatic function is associated with pathological conditions. The presence of placental lymphatics is still
under debate. This study evaluates the placental podoplanin expression in normotensive and preeclamptic women with and without
HIV.
Materials and methods: Normotensive (n = 60) and preeclamptic (n = 120) pregnant women were stratified into early and late
onset preeclampsia and further divided by HIV status. Immunostaining was performed using the podoplanin antibody prior to the
morphometric image analysis.
Results: Podoplanin was immunolocalized in a reticular-like stroma complex within the exchange and conducting villi. The
immunoexpression of podoplanin was significantly upregulated in the exchange villi (P = 0.001) irrespective of the pregnancy type and
HIV status. Based on pregnancy type, podoplanin was downregulated in early onset preeclampsia (15.33 ± 4.27%) compared to late
onset preeclampsia in the exchange villi (17.85 ± 4.74%; P = 0.04). Podoplanin was upregulated in HIV+ vs. HIV- cases regardless of
pregnancy and villi type. Irrespective of pregnancy type, podoplanin immunoexpression within exchange villi was different (P = 0.008)
between the HIV+ and HIV- groups.
Conclusion: Placental fluid homeostasis is maintained by a podoplanin reticular-like complex within conducting and exchange villi,
being upregulated in HIV-positive pregnancies.
Key words: Podoplanin, HIV infection, preeclampsia, pregnancy

1. Introduction
Preeclampsia (PE) is a systemic syndrome unique to
human pregnancy affecting 5%–12% of all pregnancies
(1). Its pathogenesis is still not fully understood; however,
the placenta and the placental bed are implicated as
the source. Complex interactions at the maternal/fetal
interface lead to deficient placentation and remodeling
of spiral arteries (2). Inadequate uteroplacental perfusion
leads to an ischemic placenta with resultant endothelial
dysfunction. The hypoxic microenvironment creates an
imbalance of circulating angiogenic [vascular endothelial
growth factor (VEGF); placental growth factor (PIGF)]
and antiangiogenic factors [soluble fms-like tyrosine
kinase-1 (sFlt-1) and soluble endoglin (sEng)] (3).
In a recent study, we reported the presence of proand antiangiogenic factors in HIV-associated PE (4).
Additionally, evidence of an exaggerated expression of
inflammatory markers in the PE placenta is reported,
although the exact role of the placenta in the direct

dissemination of inflammatory cytokines remains to be
determined (5).
As early as 1627, Ascillices discovered “milky veins”,
known today as lymphatic vessels mingled among blood
capillaries (6). Lymphatic vessels transport lymph fluid,
proteins, and other cells that leak into tissues from the
bloodstream and return them to the circulatory system
(7). Both blood and lymphatic capillaries are lined by
a monolayer of endothelial cells of mesodermal origin.
The lymphatic system plays a crucial role in tissue fluid
homeostasis, immune function, fat metabolism, and
transport of proteins and macromolecules and affords
protection against viral entry (7). Impaired lymphatic
function is associated with pathological conditions such as
lymphedema and hypertension (8). Recently, an absence
of lymphatic vasculature (LYVE-1) in the chorionic villi at
term was shown (9).
Podoplanin (PDPN), also known as T1A, GP36, GP40,
Gp38, OTS8, T1A2, TI1A, T1A-2, AGGRUS, HT1A-1, and
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PA2.26, is a 40-kDa O-linked sialoglycoprotein molecule
that is selectively expressed in lymphatic endothelial
cells (LECs) but absent in normal vasculature (10). It is
specifically recognized by a novel monoclonal antibody
named D2-40, an Mr 40,000 O-linked sialoglycoprotein
that reacts with a fixation-resistant epitope on the
lymphatic endothelium. Podoplanin is regulated by
the lymphatic-specific gene Proxy-1, a master gene that
controls the development of lymphatic progenitors (11).
Studies have proven podoplanin/D2-40 to be a useful
marker in determining lymphatic invasion (12) and
demonstrating lymphatic endothelial differentiation (13).
The presence of placental lymphatics is still under
debate (10,14). Of note, lymphatic vessels would play
a role in maternal and fetal immunity by boosting
surveying of the maternal/fetal interface to combat viral
infections. HIV-positive women are at increased risk of
placental membrane inflammatory lesions (15) such as
chorioamnionitis, placental membrane inflammation,
and deciduitis (16). It is plausible to assume that the
inflammation caused by HIV infection may be a trigger
to enhance lymphangiogenesis in the placenta. Hence,
the aim of this study was to evaluate whether PDPN is
expressed in term human placentas and to compare its
expression in HIV-positive normotensive women and
those with PE.
2. Materials and methods
2.1. Study population
The study protocol was approved by the Biomedical
Research Ethics Committee of the University of KwaZuluNatal (BE: 040/12). After receiving informed consent,
the placenta was obtained from 180 pregnant women
immediately after delivery at a large urban regional
hospital. The study population consisted of normotensive
pregnant (N; n = 60) and preeclamptic (n = 120) women.
This group was further stratified based on the gestational
age into early onset PE (EOPE; <34 weeks of gestation; n =
60) and late onset PE (LOPE; >34 weeks of gestation; n =
60). Each group was further stratified by HIV status (HIVpositive and HIV-negative; n = 30 each). The groups were
thuse categorized as follows: normotensive HIV-negative
(N-), normotensive HIV-positive (N+), early onset PE
HIV-negative (EOPE-), early onset PE HIV-positive
(EOPE+), late onset PE HIV-negative (LOPE-), and late
onset PE HIV-positive (LOPE+).
Primigravid and multigravid patients with a diagnosis
of PE (new onset blood pressure of ≥140/90 mmHg and
at least 1+ proteinuria after 20 gestational weeks) formed
the study group. All study participants were delivered by
elective cesarean section.
Clinical and demographic data were recorded on
a structured data form. Exclusion criteria included

chronic hypertension, diabetes, intrauterine death,
chorioamnionitis, autoimmune diseases, cardiovascular
diseases, and a history of seizures.
2.2. Immunohistochemistry
Following delivery of the placenta, a central wedge biopsy
was fixed in 10% buffered formaldehyde, dehydrated,
and embedded in paraffin wax. Sections (3 µm) were
cut on a rotary microtome (Leica RM 2135, Germany)
and mounted onto X-tra adhesive coated slides. This
was followed by deparaffinization and rehydration in a
descending series of ethanol.
Immunostaining was performed using the Dako
Envision Flex detection system kit (K800021; Dako,
Denmark). Tissue sections were immersed into the
preheated target retrieval solution and incubated for 20 min
at 97 °C. The slides were then placed in a LINK Autostainer
instrument and immunostained using the Envision Flex
peroxidase blocking reagent for 5 min and monoclonal
mouse antihuman clone D2-40 podoplanin antibody for
20 min. Goat secondary horseradish peroxidase antibody
was added for 20 min, followed by 3,3’-diaminobenzidine
+ chromogen. Sections were counterstained with Mayer’s
hematoxylin. The lymph node served as a positive control.
Replacement of the primary antibody with a buffer or
with nonimmune serum of the same IgG class served as a
method control and IgG control, respectively. A qualitative
evaluation of PDPN immunolocalization was performed.
2.3. Morphometric image analysis of podoplanin
expression
Placental villi were viewed with an Axioscope A1
microscope (Carl Zeiss, Germany). At least four fields of
view per slide for villi type (i.e. conducting and exchange)
were randomly selected and archived at an initial objective
magnification of 20×. Image capturing, processing, and
analysis were performed using AxioVision Image Analysis
software (Version 4.8.3, Carl Zeiss, Germany). The
percentage of PDPN immunostaining (brown chromogen)
within the villi was calculated using the automeasure
mode of analysis (9). Specifically, each conducting villus
was framed and the amount of immunostaining was
expressed as percentage per frame area. However, within
the exchange villi (red), the amount of label (green) was
determined by a two-phase threshold and expressed as a
total percentage of PDPN within the frame area.
2.4. Statistical analysis
GraphPad Prism statistics software, version 5.01
(GraphPad Inc., USA) was used to analyze the data.
Descriptive statistics for continuous data are presented by
mean ± standard deviation. To determine the statistical
difference between study groups, the Kruskal–Wallis test
was used for nonparametric data. One-way ANOVA testing
was used to examine the effect of HIV infection [HIVpositive (HIV+) vs. HIV-negative (HIV-)], pregnancy type
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(normotensive vs. preeclamptic), and villus type (exchange
vs. conducting) on PDPN immunostaining. P < 0.05 was
considered statistically significant.
3. Results
3.1. Patient demographics
Demographics of the study population are shown in the
Table. Based on HIV status, a significant difference in
maternal age and birth weight was noted in the EOPE
group only (P = 0.001 and P = 0.05, respectively).
3.2. Podoplanin immunoexpression in placental tissue
Irrespective of the HIV status, villi type, and pregnancy
type (normotensive, EOPE, and LOPE), PDPN was
strongly immunostained in a reticular-like complex that
traversed the mesenchymal stroma around arteries within
the conducting (stem) and exchange villi. However, it was
absent within vascular endothelial cells of both conducting
and exchange (intermediate and terminal) villi (Figures
1 and 2). The syncytiotrophoblast and cytotrophoblast
cells population showed no immunostaining (Figure
2A). Macrophage-like cells or Hofbauer cells were
immunostained within the fetal and maternal supply.
The positive control displayed PDPN immunostaining
while buffer and method controls produced no staining.
PDPN-immunostained placental villi of normotensive
positive stem, intermediate, and terminal villi were noted
(Supplementary Figure 1).
3.3. Morphometric image analysis of podoplanin
immunostaining
3.3.1. Across the groups (N-, N+, EOPE-, EOPE+, LOPE-,
LOPE+)
Based on pregnancy type (normotensive and preeclamptic),
PDPN expression was significant in the exchange (P = 0.05)
and nonsignificant in the conducting (P = 0.274) villi.
In the exchange villi, the highest percentage of PDPN
immunoreactivity was observed in the N+ (19.99 ± 4.02%)
and LOPE+ (20.48 ± 3.2%) groups (Figure 3A). There

was a significant increase of PDPN immunoexpression in
the N- vs. N+ and EOPE+ vs. LOPE+ groups (P = 0.004
and P = 0.0001, respectively; Figure 3A). The PDPN
immunoexpression differed significantly among most of
the groups (Figure 3A).
Within the conducting villi, the N- (9.10 ± 3.18%)
and LOPE+ (9.22 ± 3.97%) groups presented the highest
PDPN immunoreactivity across all groups (Figure 3B).
A significant difference in the percentage of PDPN
immunoexpression was noted in the N- vs. EOPE+ (P =
0.009) and EOPE+ vs. LOPE+ (P = 0.04) groups. There was
an increase in PDPN immunoexpression in the EOPE+ vs.
LOPE+ groups (6.45 ± 2.77% vs. 9.22 ± 3.97%; Figure 3B).
3.3.2. Across pregnancy type (N, EOPE, LOPE)
Based on pregnancy type (normotensive and
preeclamptic), the immunoexpression of PDPN
was reduced in the preeclamptic compared to the
normotensive group (P < 0.03) regardless of HIV status
and villi type.
3.3.2.1. Exchange villi
The immunoexpression of PDPN was significantly elevated
between the EOPE and LOPE groups (15.33 ± 4.27% and
17.85 ± 4.74%, respectively; P = 0.04). Although PDPN
was high in the normotensive group (18.09 ± 5.61%), it
was not significantly different compared to the LOPE
group (P = 0.447). The PDPN immunoexpression was
lowest within the EOPE group and differed from that of
the normotensive group (P = 0.009; Figure 4A).
3.3.2.2. Conducting villi
Across pregnancy types (Normotensive 8.31 ± 2.95%
vs. EOPE 7.04 ± 3.46% vs. LOPE 8.30 ± 3.45%), PDPN
immunoexpressions within the conducting villi were not
significantly different (Figure 4B).
3.3.3. HIV status (HIV- vs HIV+)
Based on HIV status, the PDPN immunoexpression within
exchange villi was significantly different between the
HIV+ and HIV- groups (18.06 ± 4.89% and 15.59 ± 4.49%;

Table. Patient demographics across the study group.

Maternal age (years)

HIV(n = 30)
26.5 ± 6.4

HIV+
(n = 30)
27.7 ± 5.5

Pregnancy types
EOPE
HIVHIV+
(n = 30)
(n = 30)
25.2 ± 6.5** 31.8 ± 5.9**

Gestational age (weeks)

38.5 ± 1.1

38.7 ± 0.7

32.9 ± 2.6*

33 ± 3.60*

37.1 ± 6.1

37.4 ± 1.2

Baby’s weight (g)

3346 ± 321

3255 ± 396

2187 ± 799*

2083 ± 852*

3078 ± 457*

2962 ± 277*

Baby’s sex (M:F)

14:16

14:16

14:16

12:18

15:15

20:10

Parameters

Normotensive

LOPE
HIV(n = 30)
24.2 ± 6.4

HIV+
(n = 30)
26.7 ± 4.6

Data are presented as mean ± standard deviation. EOPE: Early onset preeclampsia, LOPE: late onset preeclampsia,
n: number of pregnant women per group; *P < 0.05; **P ≤ 0.001; M: male, F: female.
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Figure 1. Podoplanin-immunostained conducting villi across study groups. Rlc - Reticular-like complex; E Endothelial cells; ST - Syncytiotrophoblast. Normotensive HIV-negative (N-); normotensive HIV-positive (N+);
early onset PE HIV-negative (EOPE-); early onset PE HIV-positive (EOPE+); late onset PE HIV-negative (LOPE-),
and late onset PE HIV-positive (LOPE+). Magnification: 100 µm.
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Figure 2. Podoplanin-immunostained exchange villi across study groups. Rlc - Reticular-like complex; E Endothelial cells; ST - Syncytiotrophoblast. Normotensive HIV-negative (N-); normotensive HIV-positive (N+);
early onset PE HIV-negative (EOPE-); early onset PE HIV-positive (EOPE+); late onset PE HIV-negative (LOPE-),
and late onset PE HIV-positive (LOPE+). Magnification: 100 µm.
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Figure 3. Podoplanin immunoexpression in exchange (A) and conducting (B) villi across all study groups (n = 30
per category). *P < 0.05; **P ≤ 0.001. Normotensive HIV-negative (N-); normotensive HIV-positive (N+); early
onset PE HIV-negative (EOPE-); early onset PE HIV-positive (EOPE+); late onset PE HIV-negative (LOPE-),
and late onset PE HIV-positive (LOPE+).

Figure 4. Podoplanin immunoexpression based on pregnancy type (N, EOPE, and LOPE) within exchange (A)
and conducting (B) villi. Ns - Nonsignificant. Normotensive (N); early onset preeclampsia (EOPE); late onset
preeclampsia (LOPE).
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P = 0.008; Figure 5A) regardless of the pregnancy type.
Conversely, PDPN immunoexpression within conducting
villi was higher in the HIV- (8.25 ± 3.37%) compared to
the HIV+ (7.49 ± 3.23%) group, albeit nonsignificantly
(P = 0.142; Figure 5B). PDPN was upregulated in the
HIV+ vs. HIV- groups (11.98 ± 6.48% vs. 10.82 ± 5.66%;
P = 0.20) regardless of pregnancy and villi type. The
immunoexpression of PDPN was significantly upregulated
in the exchange villi (16.99 ± 4.99%; P = 0.001) compared
to conducting villi (7.98 ± 3.30%) irrespective of the
pregnancy type and HIV status (Figure 6).
Discussion
This study demonstrates an intense reticular-like network
of PDPN immunostaining within the mesenchymal stroma
of conducting and exchange placental villi. Regardless of
HIV status and villi type, the immunoexpression of PDPN
was reduced in PE compared to the normotensive group.
Our findings are similar to those of Wang et al. (2), who
reported a strong expression of PDPN within villous stroma
throughout gestation, albeit with a significant reduction
in PE compared to normotensive placentas. In contrast,
an upregulation of PDPN was reported in inflammatory
conditions; PE is a heightened inflammatory state (17).
We propose that the PDPN-rich stromal network within
the placental villi may serve as a lymphatic conductive

network that maintains the interstitial fluid balance in
pregnancy.
It is plausible that the complex reticular-like network
of stromal PDPN as observed in our study may be
derived from its phylogenetic and progenitor source.
These mesenchymal stromal cells are multipotent cells
that may differentiate into neurogenic, chondrogenic,
osteogenic, adipogenic, and myogenic lineages (18). We
observed that PDPN is expressed in stromal fibroblasts
and myofibroblasts. This may be associated with
lymphangiogenesis, especially as PDPN is implicated in
the lymphatic spread of cancer cells (19).
In our study, PDPN was absent in vascular endothelial
cells. The ontogeny of LECs is debatable. In mammals,
the lymphatic endothelial system seems to be exclusively
derived from the blood endothelial compartment, as
the contribution of hematopoietic cells integrating into
lymphatic structures is absent (20). In contrast, others
believe that LECs may have a dual origin, emanating either
from embryonic veins or lymphangioblasts (21).
Podoplanin may play the role of a fluid flux with different
phenotypes in perivascular cells and stroma of the placenta
(22). We observed strong immunolocalization of PDPN
in the perivascular zone of placental villi. Mesenchymal
stem cells may also differentiate into perivascular cells, the
precursors of capillary endothelial cells. Fetal blood vessels

Figure 5. Podoplanin immunoexpression according to HIV status (HIV-, n = 90 and HIV+, n = 90) within exchange (A)
and conducting (B) villi. HIV-negative: HIV- comprises N-, EOPE-, LOPE-; HIV positive: HIV+ comprises N+, EOPE+,
LOPE+. Normotensive HIV-negative (N-); normotensive HIV-positive (N+); early onset PE HIV-negative (EOPE-); early
onset PE HIV-positive (EOPE+); late onset PE HIV-negative (LOPE-), and late onset PE HIV-positive (LOPE+).
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Figure 6. Podoplanin immunoexpression within conducting
(n = 180) and exchange (n = 180) villi across the study group.
**P ≤ 0.001.

of stem villi are enclosed by perivascular tissue sheaths,
which have abundant α-actin (23).
In our study, the immunoexpression of PDPN was
reduced in PE compared to normotensive pregnancies,
irrespective of HIV status and villi type. In normal
pregnancy there is a shift from the Th1 to a Th2
immune response; however, this shift is absent in PE
(24). Podoplanin is expressed on the surface of the
proinflammatory T cells, Th17 cells, and participates in
pregnancy-related pathologies, such as PE and recurrent
spontaneous miscarriage (25).
In acute inflammation, PDPN has an inhibitory
function on T-cell response where it controls Th17 response
by reducing sensitivity to IL-7 survival signals (26). It is
plausible that PDPN serves to shut off the Th17 response,
thereby limiting the pathogenicity of these cells. This
action may be mediated through the interaction of PDPN
with its three ligands, namely CLEC-2, galectin-8, and
the chemokine CCL21 (27). During acute inflammatory
states such as PE, PDPN probably binds to either CLEC2 or galectin-8, thereby reducing CD4 effector T cells. In
the chronic state of HIV infection, PDPN interacts with
CCL21 and thus may promote chronic inflammation (26).
In our study, PDPN was upregulated in the HIV+ vs. the

HIV- group regardless of pregnancy and villi type. This
may be due to the fact that the immune insufficiency of
HIV infection is inadequate to neutralize the exaggerated
immune response in PE. Alternatively, one should note
the fact that all HIV-positive women in our study received
antiretroviral therapy. The duration and level of CD4 T-cell
counts were, however, not available.
Podoplanin can be integrated into the HIV-1 envelope,
thereby influencing HIV-1 infection by interacting with
its ligand, CLEC-2, an HIV attachment factor on platelets
(28). The interaction of HIV with CLEC-2 on platelets
might induce platelet activation and thrombocytopaenia,
which was found to be associated with HIV infection (28)
and thus has the potential to control viral expansion.
Early and late PE are thought to reflect different disease
conditions, with the former being associated with adverse
maternal and neonatal outcomes (29). In our study,
regardless of HIV status, PDPN was downregulated in the
EOPE group compared to the LOPE group in the exchange
villi. This distribution may reflect the deficient trophoblast
invasion that occurred in the EOPE group (29). In this
study, we also noticed high expression of PDPN in the
exchange compared to conducting villi. The exchange villi
constitute the site of most fetomaternal exchanges and are
comparable to alveolar type I cells in the lungs where PDPN
has a similar role to that in the placenta (30). Exchange
villi are directly bathed in maternal blood; hence, diffusion
occurs directly across this barrier, affecting interstitial
fluid accumulation.
While the presence of placental lymphatics is still under
debate, we report an absence of regular lymphatic vessels.
The presence of a reticular-lymphatic-like conductive
network within the placental stroma suggests that this
system may be involved in placental fluid homeostasis.
We demonstrated an upregulation of PDPN in HIVpositive pregnancies irrespective of the pregnancy type
and villi type. However, PDPN immunoexpression was
downregulated in the exchange villi of EOPE, reflecting
deficient trophoblast invasion. The dual paradigm of
the effect of PDPN on T-cell response in HIV infection
and pregnancy pathologies differs; hence, the functional
role of PDPN via its ligand interaction requires further
investigation.
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Supplementary Figure 1. Composite image of podoplaninimmunostained placental villi of normotensive positive stem
villi (SV), intermediate villi (IV). and terminal villi (TV), artery
(black arrow); initial magnification 5×.
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